NCT00939159View on ClinicalTrials.gov

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

PHASE2TerminatedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

LBH589

20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER